Arrowstreet Capital Limited Partnership Acquires New Stake in Omnicell, Inc. (NASDAQ:OMCL)

Arrowstreet Capital Limited Partnership bought a new position in Omnicell, Inc. (NASDAQ:OMCL) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 120,670 shares of the company’s stock, valued at approximately $5,372,000. Arrowstreet Capital Limited Partnership owned approximately 0.26% of Omnicell at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its position in Omnicell by 7.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after purchasing an additional 1,813 shares during the period. Verition Fund Management LLC purchased a new position in shares of Omnicell in the 3rd quarter valued at approximately $388,000. Geode Capital Management LLC lifted its stake in shares of Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after buying an additional 2,877 shares during the period. Franklin Resources Inc. lifted its position in Omnicell by 49.9% during the 3rd quarter. Franklin Resources Inc. now owns 30,807 shares of the company’s stock worth $1,316,000 after acquiring an additional 10,260 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in shares of Omnicell by 4.3% during the fourth quarter. Nordea Investment Management AB now owns 121,722 shares of the company’s stock worth $5,372,000 after purchasing an additional 5,068 shares during the period. Institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on OMCL shares. Benchmark restated a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Wells Fargo & Company reduced their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Monday, March 24th. Finally, Bank of America reduced their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Price Performance

Omnicell stock opened at $31.60 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of 117.04, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company’s 50 day simple moving average is $37.91 and its 200-day simple moving average is $42.16. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.